ESMO 24: Butterfly Effect? J&J’s Rybrevant Looks Beyond Lung Cancer

 
• By Alexandra Shimmings

New Phase II data for the bispecific antibody show promise in colorectal cancer as the company seeks to spread the bispecific antibody’s wings. Phase III trials are on the horizon, where it will need to go up against standard of care.    

esmo entrance
ESMO 24 in Barcelona, Spain • Source: ESMO

More from ESMO

More from Conferences